{"schema_version":"1","generated_at":"2026-11-10T18:42:14.104Z","data_as_of":null,"url":"https://www.findmykol.com/kol/hugo-hool","json_url":"https://www.findmykol.com/kol/hugo-hool/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"hugo-hool","name":"Hugo Hool","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Torrance","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1417944489","openalex":"A5061205710"},"summary":"Hugo Hool is an Oncology physician. OpenAlex indexes 10 publications with 503 citations (h-index 4).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":10,"cited_by_count":503,"h_index":4,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":24,"program_years":{"first":2021,"last":null},"rows_total":65,"shown":3,"withheld":62,"rows":[{"payer":"Janssen","program_year":2025,"amount_usd":63963,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1417944489"},{"payer":"Ipsen","program_year":2025,"amount_usd":19008.5,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1417944489"},{"payer":"Exelixis","program_year":2025,"amount_usd":8507,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1417944489"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1417944489","source":"payments"},"prescribing":{"data_year":2024,"areas_total":8,"areas_shown":3,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":50.1,"classes_total":6,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":42.6,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":13},{"class":"Serotonin-3 Receptor Antagonist","setting":"administered","share_pct":7,"drugs":[{"name":"Granisetron hydrochloride","share_pct":100}],"max_beneficiaries":18}]},{"area":"Cardiovascular","share_pct":43.1,"classes_total":1,"classes":[{"class":"Heparins or heparinoids for topical use","setting":"administered","share_pct":43.1,"drugs":[{"name":"Heparin sodium","share_pct":100}],"max_beneficiaries":22}]},{"area":"Sensory organs","share_pct":4.3,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"mixed","share_pct":4.3,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":98.9},{"name":"Dexamethasone","share_pct":1.1}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":99.7,"facility_pct":0.3},"source":"medicare"},"publications":{"total":10,"shown":5,"withheld":5,"matched_by":"OpenAlex author record","recent":[{"title":"Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","year":2026,"journal":"The Lancet","source_url":"https://doi.org/10.1016/s0140-6736(26)01254-7","status":"verified"},{"title":"Abstract PO5-19-08: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial","year":2024,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.sabcs23-po5-19-08","status":"verified"},{"title":"Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.","year":2023,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","status":"verified"},{"title":"Abstract OT3-25-01: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial","year":2023,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.sabcs22-ot3-25-01","status":"verified"},{"title":"Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.","year":2022,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps624","status":"verified"}],"source":"works"},"contact":{"address_1":"3285 SKYPARK DR","city":"Torrance","state":"CA","zip":"905055004","phone":"310-750-3300","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1417944489","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":62,"publications":5}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2019-12-27","provider_certified":"2019-12-27","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}